Form 4: Protagenic Therapeutics Director Acquires Options in PTIX

Director Timothy R. Wright acquired options for 21,250 shares of Protagenic Therapeutics (PTIX) common stock on March 25, 2024.

Summary

• On March 25, 2024, Timothy R. Wright, a director of Protagenic Therapeutics, Inc. (PTIX), acquired options to purchase 21,250 shares of PTIX common stock.
• The options have an exercise price of $1.74.
• The options vest monthly over 24 months starting from the grant date, with full acceleration upon a change of control.
• The options expire on March 25, 2034.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of an insider transaction. The director's purchase of options could be seen as slightly positive, but it's not a major event.

Positives

• A director's acquisition of options can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Protagenic Therapeutics, PTIX, Form 4, Director, Timothy R. Wright, Options, Beneficial Ownership, Securities